Proceedings of the Ninth International Conference of Drug Regulatory Authorities (ICDRA) - Berlin, Germany 25-29 April 1999
(1999; 102 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuOpening Ceremony
Ouvrir ce répertoire et afficher son contenuGood regulatory practice
Ouvrir ce répertoire et afficher son contenuGood certification practice
Ouvrir ce répertoire et afficher son contenuCounterfeit drugs: challenges and solutions
Ouvrir ce répertoire et afficher son contenuCurrent issues in regulation and quality
Ouvrir ce répertoire et afficher son contenuInternational Conference on Harmonization: implementation and implications
Ouvrir ce répertoire et afficher son contenuDrug utilization studies
Ouvrir ce répertoire et afficher son contenuInternational Conference on Harmonization and the common technical document
Ouvrir ce répertoire et afficher son contenuKeynote address
Ouvrir ce répertoire et afficher son contenuGlobal and national efforts to reduce tobacco use
Ouvrir ce répertoire et afficher son contenuElectronic communication in the regulatory process
Ouvrir ce répertoire et afficher son contenuTransparency in monitoring the safety of medicines
Ouvrir ce répertoire et afficher son contenuPharmaceutical products for use in special groups
Ouvrir ce répertoire et afficher son contenuNeed for Bioequivalence
Fermer ce répertoireAntimicrobial resistance: battling the bugs
Afficher le documentCountry experience in implementing antimicrobial resistance strategies
Afficher le documentVeterinary, aquaculture and agricultural use’ of antimicrobials contributing to resistance
Afficher le documentThe role of regulators in the containment of resistance
Afficher le documentRecommendations
Ouvrir ce répertoire et afficher son contenuSafety issues of plasma-derived medicinal products
Ouvrir ce répertoire et afficher son contenuHerbal medicines
Ouvrir ce répertoire et afficher son contenuRegulation and access to essential drugs
Afficher le documentParticipants
Afficher le documentBack cover
 

The role of regulators in the containment of resistance

Dr M. Inoue, Japan

Transportation of meat and agricultural products has increased as a consequence of continuous population growth, urbanization, extensive movement of people, and liberalization of the market. As a result, outbreaks of new and existing infectious diseases on a global scale have been generated, including the spread of infection by resistant bacteria.

Development and clinical application of new antimicrobial drugs has been followed by the emergence of resistant bacteria several years later. Thus, a cycle of use of antimicrobial drugs and emergence of resistant bacteria has been repeated. Japan is not an exception to this trend.

Multiple drug-resistant Shigella emerged in the 1950s, multiple drug resistant Staphylococcus aureus appeared in the ig6os, and ampicillin-resistant enterobacterium and Pseudomonas aeruginosa emerged in the 1970s. Recently, attention has been drawn to the emergence of multiresistent S. aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), beta -lactamase-negative penicillin-resistant Haemophilus influenzae (called BLANAR) and GISA, as well as to that of carbapenem-resistant Pseudomonas aeruginosa and Serratia.

Resistant bacteria which have emerged as a result of carbapenem hydrolysis of bacteria, Pseudomonas aeruginosa, in particular, have raised a problem unique to Japan. However, such resistant bacteria have been confined to some specific hospitals, and have not been a uniform phenomenon of all bacteria isolated in Japan.

Emergence of drug-resistant bacteria is often closely associated with the status of the use of antimicrobial drugs. However, when biochemical analysis of the mechanism of drug resistance, analysis of drug-resistant genes and identification of resistant bacteria by DNA diagnosis are taken into consideration globally, the inevitable conclusion is that other factors are also involved.

An antimicrobial agent which is suspected of losing its effectiveness because of emergence of resistant bacteria would normally be eliminated during the development stage. Therefore, there must have been no reason for concern about the emergence of resistance at that time. If resistant isolates to these drugs emerged, it must be assumed that the users or some other factors, but not the drugs themselves, were responsible.

When the types of enzyme-producing genes isolated in Japan were compared with those isolated in Europe and the United States, where they have caused a problem, identical types were not detected. Instead, two types of enzymes which are unique to Japan, were found. These results indicate that the emergence of resistant bacteria depends upon differences in the kinds of antimicrobial drugs in each country.

Why do antimicrobial agents become ineffectual? How can resistant bacteria appear in clinical settings? The evidence suggests that several genes will undergo mutation until strong resistance against cefalosporin, which is currently used in clinical settings, is established. It also suggests that it is not easy for bacteria to acquire strong resistance.

The development of antimicrobial drugs has been slowing down. It has been suggested that we cannot expect in the near future the brilliant achievements we saw in the ig8os. It is therefore crucial that, by wisely using these drugs, we prevent the emergence of resistant bacteria and maintain the efficacy of antimicrobial drugs which are currently employed in the treatment of infectious diseases in clinical settings.

Accordingly, the Japanese Ministry of Health and Welfare has recommended that the Government develop a comprehensive law aimed at preventing infectious diseases. This legislation would focus on the treatment of disease, and would stipulate ways to prevent infection and to deal with diseases when they break out. The law would cover seventy types of infectious diseases, including VRE, MRSA, and PRSP infections, and categorize them into four types based on their infectious ability and symptoms. The proposed law represents a change from current legislation, which simply requires quarantine to prevent epidemics. In conclusion, applied research should be conducted in order to use our scientific knowledge and skills for the benefit of society.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013